About
Technology
Issues
FAQ
Links
Official Page
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.